Century Therapeutics SVP granted RSUs, options

Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards.

Rhea-AI Filing Summary

Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards. He was granted 110,000 restricted stock units, each representing one share of common stock, vesting 25% on February 2, 2027 and the remaining 75% quarterly over three years, subject to continued service.

He was also granted a stock option for 225,000 shares at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the remaining 75% in 36 equal monthly installments, expiring on February 2, 2036. After these grants, he beneficially owns 514,874 common shares directly and 225,000 options.

Insider Trade Summary

Grant/Award: 335,000 shares

Grant/Award 2 txns

Insider Carr Douglas

Role SVP Finance & Operations

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	225,000	$0.00	$0.00
Grant/Award	Common Stock	110,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 225,000 contracts (Direct); Common Stock — 514,874 shares (Direct)

Footnotes (2)

1. F1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
2. F2. The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did Century Therapeutics (IPSC) grant to Douglas Carr?

Century Therapeutics granted SVP Finance & Operations Douglas Carr 110,000 restricted stock units and a stock option for 225,000 shares at an exercise price of $1.84 per share. Both awards vest over several years, contingent on his continued service.

How do Douglas Carr’s RSUs at Century Therapeutics (IPSC) vest?

Douglas Carr’s 110,000 RSUs vest 25% on February 2, 2027. The remaining 75% vest on a quarterly basis over the following three years. Each RSU converts into one share of Century Therapeutics common stock, provided he continues serving through each vesting date.

What are the terms of Douglas Carr’s stock option grant at Century Therapeutics (IPSC)?

Douglas Carr received a stock option for 225,000 shares of Century Therapeutics common stock with an exercise price of $1.84 per share. The option vests 25% on February 2, 2027, then 75% in 36 equal monthly installments, and expires on February 2, 2036.

How many Century Therapeutics (IPSC) shares does Douglas Carr own after these grants?

Following the reported transactions, Douglas Carr beneficially owns 514,874 shares of Century Therapeutics common stock directly. He also holds 225,000 stock options tied to the new grant, providing rights to purchase additional shares if vesting and exercise conditions are satisfied.

Are Douglas Carr’s reported Century Therapeutics (IPSC) holdings direct or indirect?

The Form 4 lists Douglas Carr’s post-transaction holdings of 514,874 common shares and 225,000 stock options as direct ownership. No nature-of-ownership footnote indicates a trust, LLC, or other intermediary entity for these specific awards and holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance & Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A(1)		110,000	A	$0	514,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.84	02/02/2026		A		225,000		(2)	02/02/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

2. The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Douglas Carr	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.